Repligen Corporation (NASDAQ:RGEN) will unveil its latest earnings on Thursday, August 2, 2012. Repligen is a biopharmaceutical company focused primarily on the development of novel therapeutics for radiology and neuropsychiatry.
Repligen Corporation Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of one cent per share after the company broke even in the year-earlier quarter.
Investing Insights: Is TV the Next Bullish Catalyst for Apple’s Stock?
A Look Back: In the first quarter, the company swung to a profit of $1.2 million (4 cents a share) from a loss of $2 million (6 cents) a year earlier. Revenue rose more than twofold to $12.8 million from $5.9 million.
Stock Price Performance: Between May 2, 2012 and July 27, 2012, the stock price fell 67 cents (-14.4%), from $4.66 to $3.99. The stock price saw one of its best stretches over the last year between March 23, 2012 and April 3, 2012, when shares rose for eight straight days, increasing 29.2% (+$1.44) over that span. It saw one of its worst periods between July 13, 2012 and July 20, 2012 when shares fell for six straight days, dropping 10% (-43 cents) over that span.
Balance Sheet Analysis: The company’s current ratio of assets to liabilities came in at 5.77 last quarter. Having a ratio above 2:1 is usually considered a good indicator of a company’s liquidity and ability to meet creditor demands. The company regressed in this liquidity measure from 6.28 in the fourth quarter of the last fiscal year to the last quarter driven in part by an increase in liabilities. Current liabilities increased 17.8% to $8.8 million while assets rose 8.2% to $50.7 million.
On the top line, the company is looking to build on four-straight revenue increases heading into this earnings announcement. Revenue rose 9.2% in the first quarter, 18.1% in the second quarter of the last fiscal year and 1.4% in the fourth quarter of the last fiscal year before increasing again in the first quarter.
The company’s gross margin shrank by 12.8 percentage points in the in the first quarter. Revenue rose 117.1% while cost of sales rose 210.1% to $5.5 million from a year earlier.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories: